Literature DB >> 21463831

MicroRNA therapeutics in preclinical cancer models.

Minlee Kim1, Andrea L Kasinski, Frank J Slack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21463831     DOI： 10.1016/S1470-2045(11)70067-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  23 in total

1.  A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer.

Authors:  Ning Li; Sippy Kaur; Joel Greshock; Heini Lassus; Xiaomin Zhong; Yanling Wang; Arto Leminen; Zhongjun Shao; Xiaowen Hu; Shun Liang; Dionyssios Katsaros; Qihong Huang; Ralf Bützow; Barbara L Weber; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2011-11-04       Impact factor: 12.701

Review 2.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

3.  Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.

Authors:  Esteban A Orellana; Chennan Li; Alexa Lisevick; Andrea L Kasinski
Journal:  Cell Cycle       Date:  2019-07-01       Impact factor: 4.534

Review 4.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

5.  Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma.

Authors:  Bing Li; Yilin Wang; Shiting Li; Hua He; Fengbin Sun; Chunlin Wang; Yicheng Lu; Xiaoqiang Wang; Bangbao Tao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

6.  Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Authors:  Amanda Tivnan; Wayne Shannon Orr; Vladimir Gubala; Robert Nooney; David E Williams; Colette McDonagh; Suzanne Prenter; Harry Harvey; Raquel Domingo-Fernández; Isabella M Bray; Olga Piskareva; Catherine Y Ng; Holger N Lode; Andrew M Davidoff; Raymond L Stallings
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation.

Authors:  Matteo J Marzi; Eleonora M R Puggioni; Valentina Dall'Olio; Gabriele Bucci; Loris Bernard; Fabrizio Bianchi; Marco Crescenzi; Pier Paolo Di Fiore; Francesco Nicassio
Journal:  J Cell Biol       Date:  2012-10-01       Impact factor: 10.539

Review 8.  MiRNA-based therapeutic intervention of cancer.

Authors:  Srivatsava Naidu; Peter Magee; Michela Garofalo
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

Review 9.  MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.

Authors:  Tomohiro Fujiwara; Toshiyuki Kunisada; Ken Takeda; Koji Uotani; Aki Yoshida; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Biomed Res Int       Date:  2014-08-04       Impact factor: 3.411

10.  Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow.

Authors:  L Liao; X Yang; X Su; C Hu; X Zhu; N Yang; X Chen; S Shi; S Shi; Y Jin
Journal:  Cell Death Dis       Date:  2013-04-18       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.